Literature DB >> 2305666

Sulindac suppression of colorectal polyps in Gardner's syndrome.

W G Friend1.   

Abstract

Sulindac causes both regression and suppression of colorectal polyps in patients with Gardner's syndrome and familial polyposis coli. Three patients with Gardner's syndrome and multiple colonic polyps had complete regression of polyps after two to three months of sulindac therapy. The implication that sulindac may prevent colorectal cancer and prophylactic surgery in patients with hereditary polyps of the colon is intriguing but has not yet been substantiated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2305666

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  7 in total

1.  Effects of sulindac on sporadic colorectal adenomatous polyps.

Authors:  N Matsuhashi; A Nakajima; Y Fukushima; Y Yazaki; T Oka
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 2.  Aspirin, NSAIDs, and digestive tract cancers.

Authors:  M J Thun
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 3.  Current ideas in desmoid tumours.

Authors:  N Julian H Sturt; Susan K Clark
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

4.  The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration.

Authors:  G Winde; H G Gumbinger; H Osswald; F Kemper; H Bünte
Journal:  Int J Colorectal Dis       Date:  1993-03       Impact factor: 2.571

5.  Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice.

Authors:  Hector Guillen-Ahlers; Steven A Buechler; Mark A Suckow; Francis J Castellino; Victoria A Ploplis
Journal:  Carcinogenesis       Date:  2008-05-21       Impact factor: 4.944

6.  Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.

Authors:  B A Teicher; T T Korbut; K Menon; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Effect of sulindac sulfide on metallohydrolases in the human colon cancer cell line HT-29.

Authors:  Hector Guillen-Ahlers; Jiangning Tan; Francis J Castellino; Victoria A Ploplis
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.